Wall Street analysts expect Shire PLC (NASDAQ:SHPG) to post $4.03 billion in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Shire’s earnings. The highest sales estimate is $4.07 billion and the lowest is $3.97 billion. Shire posted sales of $3.81 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.8%. The business is expected to report its next quarterly earnings results on Thursday, February 15th.
According to Zacks, analysts expect that Shire will report full year sales of $4.03 billion for the current financial year, with estimates ranging from $14.88 billion to $15.10 billion. For the next year, analysts anticipate that the company will post sales of $15.77 billion per share, with estimates ranging from $15.31 billion to $16.58 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for Shire.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. Shire’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.17 earnings per share.
Several analysts have weighed in on SHPG shares. Zacks Investment Research cut shares of Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. FBR & Co started coverage on shares of Shire in a research note on Thursday, October 19th. They set a “buy” rating and a $201.00 price objective on the stock. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a research note on Thursday, November 16th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Finally, Liberum Capital raised shares of Shire from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. Shire presently has a consensus rating of “Hold” and an average target price of $212.18.
Several hedge funds have recently made changes to their positions in SHPG. Pacer Advisors Inc. acquired a new position in shares of Shire during the second quarter worth approximately $171,000. CIBC World Markets Inc. acquired a new position in shares of Shire during the second quarter worth approximately $714,000. Stephens Inc. AR lifted its position in shares of Shire by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 228 shares in the last quarter. Seven Eight Capital LP lifted its holdings in Shire by 18.5% in the second quarter. Seven Eight Capital LP now owns 4,494 shares of the biopharmaceutical company’s stock valued at $743,000 after buying an additional 700 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Shire by 1.9% in the second quarter. PNC Financial Services Group Inc. now owns 147,777 shares of the biopharmaceutical company’s stock valued at $24,422,000 after buying an additional 2,750 shares during the period. Institutional investors own 20.19% of the company’s stock.
Shares of Shire (SHPG) opened at $147.55 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The firm has a market cap of $44,720.00, a PE ratio of 27.79, a price-to-earnings-growth ratio of 0.79 and a beta of 1.59. Shire has a 52 week low of $137.17 and a 52 week high of $192.15.
COPYRIGHT VIOLATION WARNING: “$4.03 Billion in Sales Expected for Shire PLC (SHPG) This Quarter” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/15/4-03-billion-in-sales-expected-for-shire-plc-shpg-this-quarter.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Get a free copy of the Zacks research report on Shire (SHPG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.